Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
small interfering RNA targeting TBCE
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Small interfering RNA targeting TBCE is an experimental nucleic acid therapeutic designed to silence the expression of tubulin folding cofactor E (TBCE). TBCE is a chaperone protein essential for the folding of alpha-tubulin and the subsequent formation of alpha/beta-tubulin heterodimers, which are the building blocks of microtubules. Research indicates that elevated TBCE expression is a significant driver of resistance to platinum-based chemotherapies, such as cisplatin, in hepatocellular carcinoma (HCC). By utilizing RNA interference (RNAi) to knock down TBCE mRNA, this therapeutic disrupts cytoskeleton rearrangement and microtubule dynamics, thereby sensitizing cancer cells to DNA-damaging agents and promoting apoptosis. In preclinical studies, it has been delivered via endosomal pH-responsive nanoparticles in combination with cisplatin prodrugs to overcome chemoresistance in orthotopic and patient-derived xenograft (PDX) models of liver cancer.
- Other names
- TBCE siRNAsiRNA of tubulin folding cofactor Etubulin folding cofactor E siRNA
02
Targets
TBCE (Tubulin-specific chaperone E)
Beyond the preview
Go deeper on small interfering RNA targeting TBCE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on small interfering RNA targeting TBCE.